Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avastin plus Tarceva, gemcitabine misses endpoint

Roche (SWX:ROG) said Avastin bevacizumab plus Tarceva erlotinib and gemcitabine missed the primary

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE